Filing Flows › Lipocine (LPCN) › Q3 2026 › vs Q2 2026
Lipocine (LPCN) Q3 2026 vs Q2 2026 (quarter over quarter)
Lipocine's revenue rose $2.1M (12×) from $190K in Q2 2026 to $2.3M in Q3 2026.
Lipocine, Q3 2026: revenue $2.3M (20× year over year), operating margin -37.9%, net loss $666K, operating cash flow −$1.8M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $2.3M | $190K | $2.1M | 12× |
| Other income, net | $202K | $220K | −$18K | -8% |
| Net loss | $666K | $2.6M | −$2.0M | -75% |
| Costs & expenses | $3.2M | $3.0M | $126K | +4% |
| Operating costs | $3.2M | $3.0M | $126K | +4% |
| Research & development | $2.1M | $2.0M | $29K | +1% |
| General & admin | $1.1M | $991K | $98K | +10% |
| Operating cash sources | $1.9M | $3.1M | −$1.2M | -39% |
| Depreciation & amortization | $15K | $15K | −$1 | 0% |
| Share-based compensation | $74K | $58K | $16K | +27% |
| Cash used in operations | $1.8M | $3.0M | −$1.2M | -40% |
| Net loss absorbed | $666K | $2.6M | −$2.0M | -75% |
| Working capital & other | $1.2M | $479K | $752K | +157% |
Questions
How much did Lipocine's revenue grow quarter over quarter in Q3 2026?
Lipocine's revenue rose $2.1M (12×) from $190K in Q2 2026 to $2.3M in Q3 2026.